NewAmsterdam Pharma (NAMS) Retained Earnings (2022 - 2025)
Historic Retained Earnings for NewAmsterdam Pharma (NAMS) over the last 4 years, with Q3 2025 value amounting to -$687.5 million.
- NewAmsterdam Pharma's Retained Earnings fell 4740.05% to -$687.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$687.5 million, marking a year-over-year decrease of 4740.05%. This contributed to the annual value of -$558.6 million for FY2024, which is 7622.04% down from last year.
- Per NewAmsterdam Pharma's latest filing, its Retained Earnings stood at -$687.5 million for Q3 2025, which was down 4740.05% from -$615.5 million recorded in Q2 2025.
- NewAmsterdam Pharma's 5-year Retained Earnings high stood at -$121.8 million for Q4 2022, and its period low was -$687.5 million during Q3 2025.
- Over the past 4 years, NewAmsterdam Pharma's median Retained Earnings value was -$458.1 million (recorded in 2024), while the average stood at -$443.7 million.
- Its Retained Earnings has fluctuated over the past 5 years, first crashed by 16028.81% in 2023, then tumbled by 3684.63% in 2025.
- NewAmsterdam Pharma's Retained Earnings (Quarter) stood at -$121.8 million in 2022, then crashed by 160.29% to -$317.0 million in 2023, then plummeted by 76.22% to -$558.6 million in 2024, then dropped by 23.08% to -$687.5 million in 2025.
- Its Retained Earnings stands at -$687.5 million for Q3 2025, versus -$615.5 million for Q2 2025 and -$598.1 million for Q1 2025.